Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront

Loading news article.

Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront | WAPE

Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront

Article summary

Related companies

Comments —